Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies to treat serious diseases, particularly genetic disorders. The company operates in the biopharmaceutical industry, which involves the development of medical treatments using biological sources. Abeona's primary clients are patients suffering from severe genetic conditions, especially those with high unmet medical needs, such as genetic eye disorders.

Abeona's business model revolves around researching, developing, and eventually commercializing gene therapies. Gene therapy involves using DNA to treat diseases by delivering the correct copy of a gene into a patient's cells. This approach is particularly promising for genetic disorders caused by a single genetic defect. One of Abeona's key projects is ABO 50X, which is being explored for its potential to treat genetic eye disorders.

The company generates revenue through various stages of its development process. Initially, funding comes from investors who believe in the potential of Abeona's therapies. As the therapies progress through clinical trials and receive regulatory approval, the company can then commercialize these treatments, generating income from sales and possibly licensing agreements.

Abeona Therapeutics is committed to transforming the lives of patients by harnessing the promise of genetic medicine. Their vision is to make cures the new standard of care, moving beyond treatments that only manage symptoms.

Keywords: gene therapy, genetic disorders, biopharmaceutical, cell therapy, clinical-stage, ABO 50X, ophthalmic diseases, DNA therapy, serious diseases, patient-focused.